Table 3 Heart rate variability measurements for the substantial early weight gain (EWG) and non-substantial weight gain groups (NWG). Data are presented as the means ± the standard deviation (SD)

From: Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis

Variable

EWG (n = 25)

NWG (n = 58)

P-value*

Statistics

P-value#

SDNNbaseline (ms)

85.04 ± 12.14

89.43 ± 14.30

0.180

t′ = 1.431

0.158

SDNNweek4 (ms)

88.84 ± 14.50

0.103

t′ = 3.430

0.001

LFnbaseline (n.u.)

52.68 ± 9.43

52.30 ± 8.52

0.309

t = 0.179

0.859

LFnweek4 (n.u.)

53.34 ± 7.63

0.255

t = 2.324

0.023

HFnbaseline (n.u.)

42.35 ± 9.67

42.47 ± 8.34

0.166

t′ = 0.055

0.957

HFnweek4 (n.u.)

0.475

t = 2.664

0.009

LF/HFbaseline

1.39 ± 0.71

1.38 ± 0.88

0.638

t = 0.065

0.948

LF/HFweek4

1.41 ± 0.63

0.115

t′ = 2.057

0.046

  1. SDNN: standard deviation of the NN interval; LFn: normalized low frequency power; HFn: normalized high frequency power; n.u.: normalized unit.
  2. with baseline using a paired-samples t-test, P-value < 0.05;
  3. *P-value of Levene's test for equality of variances;
  4. #P-value of independent-samples t-test.
Back to article page